Terms: = Liver cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Treatment
22 results:
1. Meta-analysis of the prognostic value of soluble programmed death ligand-1 (spd-L1) in cancers.
Sun J; Hu S; Li X
Biomarkers; 2023 Sep; 28(6):477-485. PubMed ID: 37017446
[TBL] [Abstract] [Full Text] [Related]
2. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.
Wei H; Mao Y; Zhang H; Wu F; Zhang Y
Immunol Invest; 2023 Apr; 52(3):343-363. PubMed ID: 36762677
[TBL] [Abstract] [Full Text] [Related]
3. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.
Chen L; Liu S; Adah D; Sun Q; Liang Z; Ho M; Sun B
Immunology; 2023 Jun; 169(2):204-218. PubMed ID: 36640111
[TBL] [Abstract] [Full Text] [Related]
4. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients.
Xiaochen M; Xiangyang S; Fubo X; Wencheng J; Qingliang W; Yang X; Caixia L; Kai Z
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e515-e523. PubMed ID: 35289092
[TBL] [Abstract] [Full Text] [Related]
5. Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment.
Kozuka R; Enomoto M; Dong MP; Hai H; Thuy LTT; Odagiri N; Yoshida K; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Tamori A; Kawada N
Sci Rep; 2022 Jan; 12(1):105. PubMed ID: 34996935
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic value of soluble programmed cell death-1 (spd-1) and soluble programmed cell death ligand-1 (spd-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
[TBL] [Abstract] [Full Text] [Related]
7. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma.
Na BG; Kim YK; Hwang S; Lee KJ; Park GC; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Yang H; Yoon YI; Tak E; Park YH; Lee SG
Medicine (Baltimore); 2021 Apr; 100(17):e25640. PubMed ID: 33907121
[TBL] [Abstract] [Full Text] [Related]
8. Serum levels of soluble programmed death-ligand 1 (spd-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
[TBL] [Abstract] [Full Text] [Related]
9. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization.
Ma XL; Qu XD; Yang WJ; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Clin Chim Acta; 2020 Dec; 511():67-74. PubMed ID: 32979338
[TBL] [Abstract] [Full Text] [Related]
10. Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma.
Dong MP; Enomoto M; Thuy LTT; Hai H; Hieu VN; Hoang DV; Iida-Ueno A; Odagiri N; Amano-Teranishi Y; Hagihara A; Fujii H; Uchida-Kobayashi S; Tamori A; Kawada N
Sci Rep; 2020 Feb; 10(1):3392. PubMed ID: 32099055
[TBL] [Abstract] [Full Text] [Related]
11. Multicenter phase II study of SOX plus trastuzumab for patients with HER2
Yuki S; Shinozaki K; Kashiwada T; Kusumoto T; Iwatsuki M; Satake H; Kobayashi K; Esaki T; Nakashima Y; Kawanaka H; Emi Y; Komatsu Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Baba H; Mori M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):217-223. PubMed ID: 31768696
[TBL] [Abstract] [Full Text] [Related]
12. Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from?
Elmezayen HA; Okabe H; Baba Y; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Hayashi H; Imai K; Chikamoto A; Yamashita YI; Baba H
Surg Today; 2020 Jun; 50(6):569-576. PubMed ID: 31760568
[TBL] [Abstract] [Full Text] [Related]
13. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract] [Full Text] [Related]
14. Sialic Acid-Functionalized pH-Triggered Micelles for Enhanced Tumor Tissue Accumulation and Active Cellular Internalization of Orthotopic Hepatocarcinoma.
Xu XL; Lu KJ; Zhu ML; Du YL; Zhu YF; Zhang NN; Wang XJ; Kang XQ; Xu DM; Ying XY; Yu RS; Lu CY; Ji JS; You J; Du YZ
ACS Appl Mater Interfaces; 2018 Sep; 10(38):31903-31914. PubMed ID: 30178997
[TBL] [Abstract] [Full Text] [Related]
15. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract] [Full Text] [Related]
16. Clinical significance of soluble programmed cell death ligand-1 (spd-L1) in hepatocellular carcinoma patients treated with radiotherapy.
Kim HJ; Park S; Kim KJ; Seong J
Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
[TBL] [Abstract] [Full Text] [Related]
17. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
18. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Terai S
Int J Med Sci; 2017; 14(5):403-411. PubMed ID: 28539815
[No Abstract] [Full Text] [Related]
19. Surgical resection and peri-operative chemotherapy for colorectal cancer liver metastases: A population-based study.
Booth CM; Nanji S; Wei X; Biagi JJ; Krzyzanowska MK; Mackillop WJ
Eur J Surg Oncol; 2016 Feb; 42(2):281-7. PubMed ID: 26558526
[TBL] [Abstract] [Full Text] [Related]
20. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract] [Full Text] [Related]
[Next]
